GSK, Telethon and OSR gene treatment for ADA-SCID approved

GlaxoSmithKline (GSK), Fondazione Telethon (Telethon) and Ospedale San Raffaele (OSR) recently announced that the European Commission has approved Strimvelis, the first ex-vivo stem cell gene therapy to treat patients with ADA-SCID (Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency). For more information please see:

Shire and Baxalta Complete Merger

Shire today completed its previously announced combination with Baxalta forming the leading global company in rare diseases therapies including for primary immunodeficiencies. IPOPI looks forward to continuing with Shire the long-standing collaboration it has had over the years with Baxalta and previously Baxter. For more information please see Shire’s official press release here.